RNA Avidity Biosciences, Inc.: Margin operasi

Avidity Biosciences, Inc. - logo grafis emiten RNA

Avidity Biosciences (RNA) develops targeted RNA therapies, ensuring long-term demand for drugs treating muscle pathologies. However, a lack of revenue and high R&D expenses leave the company dependent on clinical trials. The innovative potential of AOC technologies is confirmed by the operating margin time series, where the value remains at -194.80, signaling the current state of the business model.

aviditybiosciences.com (RNA): Rentabilitas dodolan miturut bathi operasi saka 04.07.2022 nganti 19.11.2026

Rincian metrik lan analitis perusahaan aviditybiosciences.com (RNA)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:RNA, Avidity
Produk dadi Avidity Biosciences

For Avidity Biosciences (RNA), the level of operating efficiency reflects the ability to generate profit amid geopolitical risks and the complexities of registering RNA-based drugs in foreign markets. This indicator is calculated as the ratio of operating profit to revenue, measuring the share of income after deducting all production costs but before taxes and interest, which allows for an objective assessment of the company's fundamental capital stability.

Analisis pesaing Avidity Biosciences

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|crisprtx.com - Margin dodolan operasi|Tingkat bathi operasi WGS|RARE - Rentabilitas operasi|Beam Tx (BEAM) - Margin dodolan operasi|SRPT (Sarepta Therapeutics Inc) - Margin dodolan operasi|TWST: Rasio bathi operasi|TXG (10xgenomics.com) - Margin operasi|NTLA (Intellia Therapeutics, Inc.) - Rasio bathi operasi|Rentabilitas operasi Stoke Corp (STOK)|Rentabilitas kegiatan operasi BioLife|Margin operasi WVE (Wave Life Sciences Ltd)|MAZE: Rentabilitas dodolan miturut bathi operasi|Sionna Therapeutics, Inc. - Margin operasi|Tingkat bathi operasi PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Margin dodolan operasi|QURE - Rentabilitas kegiatan operasi|MGTX (MeiraGTx Corp) - Margin operasi|Rentabilitas dodolan operasi REGENXBIO Inc. RGNX|Rentabilitas operasi Solid Biosciences (SLDB)|Ocugen Corp - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Pacific Biosciences PACB|Rasio bathi operasi BNTC (Benitec)|Design Corp - Margin operasi|Rocket Pharmaceuticals - Rasio bathi operasi|Rentabilitas dodolan miturut bathi operasi 4D Molecular Therapeutics, Inc.|Rentabilitas dodolan operasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Margin operasi|Rentabilitas dodolan operasi Editas EDIT|Margin operasi SLN|ProQR Therapeutics - Rentabilitas dodolan miturut bathi operasi|Margin operasi CDXS (Codexis, Inc.)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi